## Lung Selectivity and Systemic Absorption of ICS **Key Point:** Budesonide is a **non-halogenated** inhaled corticosteroid with high lung selectivity and moderate systemic bioavailability (~10–15%), but extensive first-pass hepatic metabolism limits systemic effects. It is one of the most widely studied ICS agents in clinical practice. ### ICS Classification: Halogenated vs. Non-Halogenated | Agent | Halogenation | Lung Selectivity | Systemic Bioavailability | Notes | | --- | --- | --- | --- | --- | | **Budesonide** | **Non-halogenated** | High | 10–15% | Non-halogenated; high first-pass metabolism | | Mometasone furoate | Halogenated (fluorine at C9) | Very high | 2–5% | Contains fluorine — halogenated | | Fluticasone propionate | Halogenated (fluorine) | High | 1–2% | Highly lipophilic | | Fluticasone furoate | Halogenated (fluorine) | High | <1% | Enhanced potency | | Ciclesonide | Halogenated (chlorine) | Very high | <1% | Prodrug; activated in lungs | **High-Yield:** Among the options listed, **Budesonide** is the only truly non-halogenated compound. Mometasone furoate, despite its low systemic bioavailability, contains a fluorine atom at C9 and is therefore a **halogenated** steroid. Ciclesonide contains a chlorine substituent (halogenated), and both fluticasone compounds are fluorinated. **Clinical Pearl:** Budesonide's non-halogenated structure, combined with rapid hepatic first-pass metabolism of systemically absorbed drug (~90% inactivated), gives it an excellent safety profile. It is approved for use in pregnancy (Category B) and is widely used in pediatric asthma and COPD management. **Mnemonic:** **BUD**esonide = **B**are of halogens (**U**nhalogenated **D**rug). [cite: KD Tripathi 8e Ch 26; Brunton LL, Goodman & Gilman's Pharmacological Basis of Therapeutics, 13e]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.